Developer docs
API playgroundTry for free, no card

Search company profiles

Genoskin

Full company profile

uuid000047p

Namestring
Genoskin
Legal namestring
GENOSKIN SAS
Websiteurl
genoskin.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Genoskin is a French-headquartered biotechnology contract research organization (CRO) that develops and supplies ex vivo human skin models as alternatives to animal testing for pharmaceutical, biotechnology, medical device, cosmetics, and chemicals customers. The company's core technology is a proprietary, patented process that keeps donated human skin alive for up to seven days post-surgery, preserving all cell types and skin structures so that drug developers can perform a full week of testing on living, immunocompetent human tissue rather than animal models or reconstructed epidermis.

The product portfolio comprises standardized ready-to-use platforms — NativeSkin (live full-thickness human skin), HypoSkin (subcutaneous injection testing), InflammaSkin (psoriasis/inflammatory model), WoundSkin (wounded skin for healing and infection studies), HairSkin and FacialSkin (facial-surgery-derived tissue), FrozenSkin, HistoSkin (FFPE sections), proprietary culture medium, and human primary mast cells — supplemented by a services layer including non-clinical toxicity studies (ISR Platform), local tolerance studies, vaccine immunoprofiling, topical/transdermal testing, spatial biology (Mantis), and bioinformatics analysis.

Revenue is generated through three streams: (i) one-time unit sales of standardized skin models and skin derivatives via three regional e-commerce storefronts (US, EU/Middle East, APAC) priced between roughly $99 and $1,250 per unit, (ii) custom non-clinical research services priced via bespoke study plans with 50% initiation payments and rapid 2-week study initiation, and (iii) ancillary sales of mast cells and proprietary culture medium. The company operates from Toulouse, France (HQ) and Salem, Massachusetts (US operations), serves 490+ customers with 75% of the top 20 large pharma companies already partnered, and has produced 90+ peer-reviewed publications using its models.

Short descriptiontext

Genoskin is a French-headquartered biotech CRO that provides ex vivo human skin models and custom non-clinical research services as human-relevant, animal-testing alternatives to pharmaceutical, biotech, medical device, cosmetics, and chemicals customers across North America, Europe, and Asia-Pacific.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSalem, United States
HQ citystring
Salem
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ex vivo skin models, preclinical CRO services, animal testing alternatives, human skin biology, drug safety testing
Industry3 codes
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Skin Model Products
TypeOne Time License
Description

Sale of standardized and custom ex vivo human skin models (NativeSkin, HypoSkin, WoundSkin, etc.) and skin derivatives (FrozenSkin, HistoSkin FFPE) through e-commerce shops for US, EU, and APAC markets. Products sold per model/unit with pricing varying by size, customization, and donor specifications.

genoskin.com
2Custom Non-Clinical Services
TypeProfessional Services
Description

Tailored research services including non-clinical toxicity studies, local tolerance studies, inflammatory disease research, vaccine development, and topical/transdermal services. Services require 50% initiation payment and custom study plans.

genoskin.com
3Mast Cells and Culture Media
TypeOne Time License
Description

Sale of in vitro-derived mast cells (sold in increments of 1, 2, and 5 million cells per donor) and proprietary culture medium for maintaining skin models in culture.

genoskin.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details17 tiers
1NativeSkin Access 8mm standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$99-$109 per model (US). Standard donor specifications included.

shop-us.genoskin.com
2NativeSkin Access 8mm custom
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$119-$129 per model (US). Custom donor age, gender, phototype specifications.

shop-us.genoskin.com
3NativeSkin Access 11mm standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$119-$129 per model (US).

shop-us.genoskin.com
4NativeSkin Access 20mm standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$210-$220 per model (US).

shop-us.genoskin.com
5HypoSkin 20mm standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$350-$360 per model (US).

shop-us.genoskin.com
6HypoSkin 20mm custom
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$410-$420 per model (US).

shop-us.genoskin.com
7WoundSkin 8mm standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$149-$159 per model (US).

shop-us.genoskin.com
8WoundSkin 11mm standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$160-$170 per model (US).

shop-us.genoskin.com
9Tape Stripped NativeSkin 8mm standard
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$185-$195 per model (US). Mechanically altered skin barrier model.

shop-us.genoskin.com
10Culture Medium
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$206-$216 per 100mL bottle.

shop-us.genoskin.com
11FrozenSkin 20 cm²
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$500 per unit (US).

shop-us.genoskin.com
12FrozenSkin 50 cm²
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$1,250 per unit (US).

shop-us.genoskin.com
13HistoSkin FFPE Skin Slide
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$150 per section (US). Minimum order 5 slides.

shop-us.genoskin.com
14HistoSkin FFPE Skin Block
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$375 per unit (US).

shop-us.genoskin.com
15HypoSkin Injection Training
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$2,500 per in-person training session.

shop-us.genoskin.com
16HypoSkin Virtual Expert Consultation
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$300 per consultation.

shop-us.genoskin.com
17EU pricing (EUR)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

EU pricing approximately 10-15% lower than US pricing in EUR equivalent. NativeSkin Access 8mm: €79-€99, HypoSkin 20mm: €350-€360, WoundSkin 8mm: €149-€159.

shop-eu.genoskin.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 12 records shown
1NativeSkin
Description

Ex vivo live human skin model platform for testing pharmaceutical, cosmetic and chemical products

genoskin.com
+11 more records
Core offering1 text field

Genoskin develops and sells standardized ex vivo human skin models derived from donated surgical tissue and provides custom contract research services using those models. Its products include the NativeSkin, HypoSkin, InflammaSkin, and WoundSkin platforms, alongside biological inputs (Human Mast Cells, HistoSkin FFPE sections, FrozenSkin) and analytical services spanning topical/transdermal testing, subcutaneous injection studies, vaccine immunoprofiling, local tolerance studies, spatial biology (Mantis), and bioinformatics. Customers are pharmaceutical, biotech, medical device, cosmetics, and chemicals companies seeking human-relevant preclinical testing that reduces reliance on animal models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 75% of leading top 20 large pharma companies have partnered with Genoskin
+1 more record
Product overview1 text field

Genoskin is a biotechnology CRO offering a comprehensive portfolio of ex vivo human skin platforms and related services for drug development, safety assessment, and dermatological research. The core product line includes NativeSkin® (live human skin models), NativeSkin access® (on-demand versions for in-house use), HypoSkin® (for injection testing), InflammaSkin® (psoriasis model), WoundSkin® (wounded skin model), and human mast cells. Supporting services encompass non-clinical toxicity testing (ISR Platform®, local tolerance studies), vaccine development, topical/transdermal services, spatial biology (Mantis platform), and bioinformatic analysis. The product ecosystem is complemented by skin derivatives including HistoSkin (FFPE slides/blocks), FrozenSkin, Culture Medium, FacialSkin, and HairSkin. Services can be ordered through regional e-shops (US, EU, APAC) or via custom study requests, with study initiation possible within 2 weeks.

Product and service19 records
1NativeSkin
CategoryEx vivo human skin model
Description

Standardized full-thickness ex vivo human skin model intended for pharmaceutical, biotech, cosmetics, and chemical industry customers conducting preclinical dermatology, toxicology, and efficacy studies without animal testing.

2NativeSkin access
CategoryEx vivo human skin model
Description

On-demand variant of NativeSkin offered through Genoskin's regional online shops, providing direct access to shipped skin models for independent customer testing.

3HypoSkin
CategoryEx vivo human skin model
Description

Ex vivo human skin model designed for subcutaneous injection testing, medical device injection training, and related preclinical applications.

4InflammaSkin
CategoryDisease-specific ex vivo skin model
Description

Ex vivo skin model with induced psoriatic inflammation for pharmaceutical R&D customers researching psoriasis therapeutics and anti-inflammatory compounds.

5WoundSkin
CategoryDisease-specific ex vivo skin model
Description

Ex vivo wounded skin model for medical device, dermatology, and wound care customers evaluating wound healing, tissue repair, and topical therapeutics.

6FacialSkin
CategoryEx vivo human skin model
Description

Ex vivo skin model sourced from facial donor tissue for cosmetics customers needing facial-specific skin testing of ingredients and finished products.

7HairSkin
CategoryEx vivo human skin model
Description

Ex vivo skin model with intact hair follicles for cosmetics and pharmaceutical customers researching hair biology, hair growth, and depilation products.

8HypoSkin Injection Training
CategoryTraining service
Description

Service using HypoSkin models for hands-on training of subcutaneous injection techniques for medical device, aesthetics, and pharmaceutical customers.

9HypoSkin Virtual Expert Consultation
CategoryConsulting service
Description

Expert consultation service providing virtual guidance from Genoskin scientists on subcutaneous injection study design and interpretation.

10ISR Platform
CategoryRegulatory testing platform
Description

Standardized immunosafety assessment platform providing regulatory-grade data on topical, injectable, and biologic immunogenicity for pharmaceutical and biotech customers.

11Topical and Transdermal Testing Services
CategoryContract research service
Description

Custom contract research service evaluating topical and transdermal drug delivery, skin penetration, and ingredient efficacy on ex vivo human skin.

12Vaccine Immunoprofiling Services
CategoryContract research service
Description

Custom service profiling immune responses to vaccines and biologics using ex vivo human skin models for pharmaceutical and biotech customers.

13Local Tolerance Studies
CategoryContract research service
Description

Custom contract research service evaluating local tolerance and biocompatibility of drugs, medical devices, and chemicals on ex vivo human skin.

14Spatial Biology Analysis (Mantis)
CategoryAnalytical service
Description

Analytical service delivering high-resolution spatial tissue analysis on ex vivo human skin samples for pharmaceutical, biotech, and cosmetics customers.

15Bioinformatic Analysis
CategoryAnalytical service
Description

Bioinformatics and data interpretation service supporting genomic, transcriptomic, and molecular readouts from Genoskin ex vivo skin studies.

16HistoSkin
CategoryBiological input
Description

FFPE-preserved human skin sections sold as a biological input for histology, immunohistochemistry, and molecular analyses by external research customers.

17FrozenSkin
CategoryBiological input
Description

Frozen human skin sections sold as a biological input for downstream molecular and histological analyses by research customers.

18Culture Medium
CategoryBiological input
Description

Proprietary culture medium formulated to maintain ex vivo human skin viability, sold as a supporting product to skin model customers.

19Human Mast Cells
CategoryBiological input
Description

Primary human mast cells sold as a standalone biological input for immunology, inflammation, and allergy research customers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Collaboration presented at SOT Annual Meeting 2026 demonstrating HypoSkin ex vivo human skin platform successfully detects toxic control formulations for local tolerance screening. Study validates platform as translational human-based alternative to animal testing with demonstrated sensitivity and in vitro-in vivo correlation through macroscopic imaging and histopathology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MatTek is the most directly comparable peer, producing standardized human skin tissue models (EpiDerm, EpiDermFT, MelanoDerm) used for in vitro dermatological, toxicity, and efficacy testing. It competes head-to-head with Genoskin's NativeSkin and HypoSkin in the same pharma/cosmetics customer base with similar OECD-validated test endpoints.

TypeDirect peer
Description

Episkin, owned by L'Oréal, is a pioneer in reconstructed human epidermis models (EpiSkin, SkinEthic) for cosmetic and pharmaceutical safety testing. It is a direct competitor in reconstructed human skin models with deep scientific credibility and OECD validation, though its captive L'Oréal ownership limits commercial flexibility.

3Stratatech (Mallinckrodt)
TypeDirect peer
Description

Stratatech, a Mallinckrodt company, develops human skin tissue models including StrataGraft for wound healing research. It overlaps with Genoskin's WoundSkin and InflammaSkin product lines in serving wound healing and dermatology research customers with human-relevant skin platforms.

TypeDirect peer
Description

CellSystems is a German distributor and developer of primary human cells and 3D tissue models including skin equivalents, serving the European research market. It competes with Genoskin in the EU distribution of skin models and related cell biology reagents.

TypeDirect peer
Description

BioIVT is a major supplier of human biological specimens, including fresh and frozen human skin tissue for research and preclinical applications. It is a comparable tissue provider with overlapping customers in pharma/biotech preclinical research and similar sourcing infrastructure.

TypeBroad incumbent
Description

Charles River is a global CRO offering broad preclinical safety, efficacy, and research services including skin and dermal toxicology studies. It is a broad incumbent that may compete or partner with Genoskin as pharma increasingly demands NAMs within larger integrated preclinical packages.

TypeBroad incumbent
Description

Lonza is a global CDMO and life science tools provider with cell and gene therapy manufacturing, including primary cells and tissue services. Its scale and Biologics 21st-century strategy position it as a potential partner or competitor for advanced NAM service offerings.

TypeBroad incumbent
Description

Evotec is a global drug discovery and development CRO offering preclinical, translational, and manufacturing services. Its Just-Evotec Biologicals and broader CRO platform overlap with Genoskin's drug development customer base and could expand into NAM-based preclinical offerings.

TypeEmerging player
Description

CellGenix develops and manufactures cell culture reagents and GMP-grade cytokines for cell and gene therapy manufacturing. While focused on reagents rather than tissue models, it serves an overlapping translational research customer base that Genoskin's immunology and mast cell offerings also target.

TypeEmerging player
Description

Crown Bioscience offers preclinical CRO services including translational platforms for immuno-oncology and inflammation. Its ex vivo and in vitro service capabilities and pharma/biotech customer base overlap with Genoskin's positioning in immunology-driven preclinical research.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genoskin

Preclinical Contract Research Servicesgenoskin.com

Genoskin is a French-headquartered biotech CRO that provides ex vivo human skin models and custom non-clinical research services as human-relevant, animal-testing alternatives to pharmaceutical, biotech, medical device, cosmetics, and chemicals customers across North America, Europe, and Asia-Pacific.

What Genoskin does

Genoskin is a French-headquartered biotechnology contract research organization (CRO) that develops and supplies ex vivo human skin models as alternatives to animal testing for pharmaceutical, biotechnology, medical device, cosmetics, and chemicals customers. The company's core technology is a proprietary, patented process that keeps donated human skin alive for up to seven days post-surgery, preserving all cell types and skin structures so that drug developers can perform a full week of testing on living, immunocompetent human tissue rather than animal models or reconstructed epidermis.

The product portfolio comprises standardized ready-to-use platforms — NativeSkin (live full-thickness human skin), HypoSkin (subcutaneous injection testing), InflammaSkin (psoriasis/inflammatory model), WoundSkin (wounded skin for healing and infection studies), HairSkin and FacialSkin (facial-surgery-derived tissue), FrozenSkin, HistoSkin (FFPE sections), proprietary culture medium, and human primary mast cells — supplemented by a services layer including non-clinical toxicity studies (ISR Platform), local tolerance studies, vaccine immunoprofiling, topical/transdermal testing, spatial biology (Mantis), and bioinformatics analysis.

Revenue is generated through three streams: (i) one-time unit sales of standardized skin models and skin derivatives via three regional e-commerce storefronts (US, EU/Middle East, APAC) priced between roughly $99 and $1,250 per unit, (ii) custom non-clinical research services priced via bespoke study plans with 50% initiation payments and rapid 2-week study initiation, and (iii) ancillary sales of mast cells and proprietary culture medium. The company operates from Toulouse, France (HQ) and Salem, Massachusetts (US operations), serves 490+ customers with 75% of the top 20 large pharma companies already partnered, and has produced 90+ peer-reviewed publications using its models.

Genoskin firmographics

Firmographics
Name
Genoskin
Legal name
GENOSKIN SAS
Website
https://genoskin.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Genoskin is a French-headquartered biotech CRO that provides ex vivo human skin models and custom non-clinical research services as human-relevant, animal-testing alternatives to pharmaceutical, biotech, medical device, cosmetics, and chemicals customers across North America, Europe, and Asia-Pacific.
Ownership category
akta.pro rank

Genoskin industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Ex vivo skin models
  • Preclinical CRO services
  • Animal testing alternatives
  • Human skin biology
  • Drug safety testing

Where Genoskin is headquartered

Location

Headquarters

HQ city
Salem
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Genoskin business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Skin Model Products: Sale of standardized and custom ex vivo human skin models (NativeSkin, HypoSkin, WoundSkin, etc.) and skin derivatives (FrozenSkin, HistoSkin FFPE) through e-commerce shops for US, EU, and APAC markets. Products sold per model/unit with pricing varying by size, customization, and donor specifications.
  2. Custom Non-Clinical Services: Tailored research services including non-clinical toxicity studies, local tolerance studies, inflammatory disease research, vaccine development, and topical/transdermal services. Services require 50% initiation payment and custom study plans.
  3. Mast Cells and Culture Media: Sale of in vitro-derived mast cells (sold in increments of 1, 2, and 5 million cells per donor) and proprietary culture medium for maintaining skin models in culture.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goNativeSkin Access 8mm standard
Unit PricingPay-as-you-goNativeSkin Access 8mm custom
Unit PricingPay-as-you-goNativeSkin Access 11mm standard
Unit PricingPay-as-you-goNativeSkin Access 20mm standard
Unit PricingPay-as-you-goHypoSkin 20mm standard
Unit PricingPay-as-you-goHypoSkin 20mm custom
Unit PricingPay-as-you-goWoundSkin 8mm standard
Unit PricingPay-as-you-goWoundSkin 11mm standard
Unit PricingPay-as-you-goTape Stripped NativeSkin 8mm standard
Unit PricingPay-as-you-goCulture Medium
Unit PricingPay-as-you-goFrozenSkin 20 cm²
Unit PricingPay-as-you-goFrozenSkin 50 cm²
Unit PricingPay-as-you-goHistoSkin FFPE Skin Slide
Unit PricingPay-as-you-goHistoSkin FFPE Skin Block
Unit PricingPay-as-you-goHypoSkin Injection Training
Unit PricingPay-as-you-goHypoSkin Virtual Expert Consultation
Unit PricingPay-as-you-goEU pricing (EUR)

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Genoskin product offering

Product offering

Core offering

Genoskin develops and sells standardized ex vivo human skin models derived from donated surgical tissue and provides custom contract research services using those models. Its products include the NativeSkin, HypoSkin, InflammaSkin, and WoundSkin platforms, alongside biological inputs (Human Mast Cells, HistoSkin FFPE sections, FrozenSkin) and analytical services spanning topical/transdermal testing, subcutaneous injection studies, vaccine immunoprofiling, local tolerance studies, spatial biology (Mantis), and bioinformatics. Customers are pharmaceutical, biotech, medical device, cosmetics, and chemicals companies seeking human-relevant preclinical testing that reduces reliance on animal models.

Product overview

Genoskin is a biotechnology CRO offering a comprehensive portfolio of ex vivo human skin platforms and related services for drug development, safety assessment, and dermatological research. The core product line includes NativeSkin® (live human skin models), NativeSkin access® (on-demand versions for in-house use), HypoSkin® (for injection testing), InflammaSkin® (psoriasis model), WoundSkin® (wounded skin model), and human mast cells. Supporting services encompass non-clinical toxicity testing (ISR Platform®, local tolerance studies), vaccine development, topical/transdermal services, spatial biology (Mantis platform), and bioinformatic analysis. The product ecosystem is complemented by skin derivatives including HistoSkin (FFPE slides/blocks), FrozenSkin, Culture Medium, FacialSkin, and HairSkin. Services can be ordered through regional e-shops (US, EU, APAC) or via custom study requests, with study initiation possible within 2 weeks.

Differentiator

Problem solved

Functional benefit

Brands

  • NativeSkin: Ex vivo live human skin model platform for testing pharmaceutical, cosmetic and chemical products
  • NativeSkin access
  • HypoSkin
  • InflammaSkin
  • WoundSkin
  • HairSkin
  • FacialSkin
  • FrozenSkin
  • HistoSkin
  • VaxSkin
  • ISR Platform
  • Mantis Platform

Products and services

  • NativeSkin Standardized full-thickness ex vivo human skin model intended for pharmaceutical, biotech, cosmetics, and chemical industry customers conducting preclinical dermatology, toxicology, and efficacy studies without animal testing.
  • NativeSkin access On-demand variant of NativeSkin offered through Genoskin's regional online shops, providing direct access to shipped skin models for independent customer testing.
  • HypoSkin Ex vivo human skin model designed for subcutaneous injection testing, medical device injection training, and related preclinical applications.
  • InflammaSkin Ex vivo skin model with induced psoriatic inflammation for pharmaceutical R&D customers researching psoriasis therapeutics and anti-inflammatory compounds.
  • WoundSkin Ex vivo wounded skin model for medical device, dermatology, and wound care customers evaluating wound healing, tissue repair, and topical therapeutics.
  • FacialSkin Ex vivo skin model sourced from facial donor tissue for cosmetics customers needing facial-specific skin testing of ingredients and finished products.
  • HairSkin Ex vivo skin model with intact hair follicles for cosmetics and pharmaceutical customers researching hair biology, hair growth, and depilation products.
  • HypoSkin Injection Training Service using HypoSkin models for hands-on training of subcutaneous injection techniques for medical device, aesthetics, and pharmaceutical customers.
  • HypoSkin Virtual Expert Consultation Expert consultation service providing virtual guidance from Genoskin scientists on subcutaneous injection study design and interpretation.
  • ISR Platform Standardized immunosafety assessment platform providing regulatory-grade data on topical, injectable, and biologic immunogenicity for pharmaceutical and biotech customers.
  • Topical and Transdermal Testing Services Custom contract research service evaluating topical and transdermal drug delivery, skin penetration, and ingredient efficacy on ex vivo human skin.
  • Vaccine Immunoprofiling Services Custom service profiling immune responses to vaccines and biologics using ex vivo human skin models for pharmaceutical and biotech customers.
  • Local Tolerance Studies Custom contract research service evaluating local tolerance and biocompatibility of drugs, medical devices, and chemicals on ex vivo human skin.
  • Spatial Biology Analysis (Mantis) Analytical service delivering high-resolution spatial tissue analysis on ex vivo human skin samples for pharmaceutical, biotech, and cosmetics customers.
  • Bioinformatic Analysis Bioinformatics and data interpretation service supporting genomic, transcriptomic, and molecular readouts from Genoskin ex vivo skin studies.
  • HistoSkin FFPE-preserved human skin sections sold as a biological input for histology, immunohistochemistry, and molecular analyses by external research customers.
  • FrozenSkin Frozen human skin sections sold as a biological input for downstream molecular and histological analyses by research customers.
  • Culture Medium Proprietary culture medium formulated to maintain ex vivo human skin viability, sold as a supporting product to skin model customers.
  • Human Mast Cells Primary human mast cells sold as a standalone biological input for immunology, inflammation, and allergy research customers.

Quantifiable outcome

  • 75% of leading top 20 large pharma companies have partnered with Genoskin
  • +1 more outcomes

Companies that use Genoskin

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Genoskin technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Genoskin partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • argenxcoreStrategic or Co-development Partner · 19 March 2026Collaboration presented at SOT Annual Meeting 2026 demonstrating HypoSkin ex vivo human skin platform successfully detects toxic control formulations for local tolerance screening. Study validates platform as translational human-based alternative to animal testing with demonstrated sensitivity and in vitro-in vivo correlation through macroscopic imaging and histopathology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Genoskin competitors and assessment

Company assessment

Direct peers

  • MatTek Life Sciences: MatTek is the most directly comparable peer, producing standardized human skin tissue models (EpiDerm, EpiDermFT, MelanoDerm) used for in vitro dermatological, toxicity, and efficacy testing. It competes head-to-head with Genoskin's NativeSkin and HypoSkin in the same pharma/cosmetics customer base with similar OECD-validated test endpoints.
  • Episkin (L'Oréal): Episkin, owned by L'Oréal, is a pioneer in reconstructed human epidermis models (EpiSkin, SkinEthic) for cosmetic and pharmaceutical safety testing. It is a direct competitor in reconstructed human skin models with deep scientific credibility and OECD validation, though its captive L'Oréal ownership limits commercial flexibility.
  • Stratatech (Mallinckrodt): Stratatech, a Mallinckrodt company, develops human skin tissue models including StrataGraft for wound healing research. It overlaps with Genoskin's WoundSkin and InflammaSkin product lines in serving wound healing and dermatology research customers with human-relevant skin platforms.
  • CellSystems Biotechnologie Vertrieb: CellSystems is a German distributor and developer of primary human cells and 3D tissue models including skin equivalents, serving the European research market. It competes with Genoskin in the EU distribution of skin models and related cell biology reagents.
  • BioIVT: BioIVT is a major supplier of human biological specimens, including fresh and frozen human skin tissue for research and preclinical applications. It is a comparable tissue provider with overlapping customers in pharma/biotech preclinical research and similar sourcing infrastructure.

Broad incumbents

  • Charles River Laboratories: Charles River is a global CRO offering broad preclinical safety, efficacy, and research services including skin and dermal toxicology studies. It is a broad incumbent that may compete or partner with Genoskin as pharma increasingly demands NAMs within larger integrated preclinical packages.
  • Lonza Group: Lonza is a global CDMO and life science tools provider with cell and gene therapy manufacturing, including primary cells and tissue services. Its scale and Biologics 21st-century strategy position it as a potential partner or competitor for advanced NAM service offerings.
  • Evotec SE: Evotec is a global drug discovery and development CRO offering preclinical, translational, and manufacturing services. Its Just-Evotec Biologicals and broader CRO platform overlap with Genoskin's drug development customer base and could expand into NAM-based preclinical offerings.

Emerging players

  • CellGenix: CellGenix develops and manufactures cell culture reagents and GMP-grade cytokines for cell and gene therapy manufacturing. While focused on reagents rather than tissue models, it serves an overlapping translational research customer base that Genoskin's immunology and mast cell offerings also target.
  • Crown Bioscience: Crown Bioscience offers preclinical CRO services including translational platforms for immuno-oncology and inflammation. Its ex vivo and in vitro service capabilities and pharma/biotech customer base overlap with Genoskin's positioning in immunology-driven preclinical research.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Genoskin social profiles

Digital presence

Genoskin financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genoskin leadership team

Management profile

Number of profiles

Profiles7 records

Genoskin funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genoskin M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genoskin

What does Genoskin do?

Genoskin develops and sells standardized ex vivo human skin models derived from donated surgical tissue and provides custom contract research services using those models. Its products include the NativeSkin, HypoSkin, InflammaSkin, and WoundSkin platforms, alongside biological inputs (Human Mast Cells, HistoSkin FFPE sections, FrozenSkin) and analytical services spanning topical/transdermal testing, subcutaneous injection studies, vaccine immunoprofiling, local tolerance studies, spatial biology (Mantis), and bioinformatics. Customers are pharmaceutical, biotech, medical device, cosmetics, and chemicals companies seeking human-relevant preclinical testing that reduces reliance on animal models.

Is Genoskin a public or private company?

Genoskin is a private company. It is classified as venture growth investor backed and is currently operating.

When was Genoskin founded?

Genoskin was founded in 2011. It employs 51 to 100 people.

Where is Genoskin based?

Genoskin is headquartered in Salem, United States, in the North America region.

How does Genoskin make money?

Three revenue lines are on record. Skin Model Products are the primary driver. The others are custom Non-Clinical Services and mast Cells and Culture Media.

Who are Genoskin's main competitors?

Direct peers on record are MatTek Life Sciences, Episkin (L'Oréal), Stratatech (Mallinckrodt), CellSystems Biotechnologie Vertrieb and BioIVT. Broad incumbents are Charles River Laboratories, Lonza Group and Evotec SE. Emerging players are CellGenix and Crown Bioscience.

Does Genoskin have an API?

No public API is recorded for Genoskin.

What industry is Genoskin in?

Genoskin's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceGenoskin Doubles US Foothold to Launch Local Primary HumanMast Cell Production for North American CustomersGenoskin is expanding its Salem, Massachusetts facility to 8,000 square feet to support local production of primary human mast cells for North American customers. The move follows a 50% capacity increase at its French site and aims to reduce shipping delays and improve supply continuity. The new lab will be operational in Q4 2026.PharmiWeb.comGenoskin Showcases HypoSkin® Ex Vivo Platform at SOT Annual MeetingGenoskin presented findings from a collaboration with argenx at the 2026 SOT Annual Meeting in San Diego, demonstrating that its HypoSkin ex vivo human skin platform successfully detects toxic control formulations for local tolerance screening. The study validates the platform as a translational human-based alternative to animal testing, showing sensitivity and in vitro-in vivo correlation through macroscopic imaging and histopathology. The non-clinical testing market is projected to grow from $108.6 billion in 2025 to $155.4 billion by 2034, reflecting mounting regulatory pressure to reduce animal testing.HrtodayNadia Kaci-Chaouche Appointed as Vice President Human Resources at GENOSKINGENOSKIN, a biotechnology company and contract research organization specializing in ex vivo human skin platforms, announced the appointment of Nadia Kaci-Chaouche as Vice President Human Resources, effective January 2026, based in Toulouse/Paris as a hybrid role. Kaci-Chaouche brings over four years of experience as Senior Director Global HR at Mnemo Therapeutics and prior HR leadership roles at Aptus Health and SMART Technologies, and will lead GENOSKIN's people strategy as the company scales its operations.Tech.euGenoskin raises $8.7M to advance human skin models as animal testing alternativeGenoskin raised $8.7 million in its first funding round, led by OCCTE with Captech Santé, GSO Innovation, and CA Toulouse 31 Initiatives. The company will use the funds to double its size within three years and expand commercial presence in Europe and Asia by 2026.PharmiWeb.comGenoskin Raises $8.7M Series A to Advance Ethical, Human-Based Models That Deliver Reliable Insights for Safer, More Predictive Drug DevelopmentGenoskin raised $8.7 million in its first funding round, led by OCCTE and others, to expand its ex vivo human skin testing platforms. The company plans to double its size within three years and open new production sites in France and the US. It also aims to launch immune-centric services by 2027.PR NewswireGenoskin launches new skin model, NativeSkin→ access, that increases accessibility to animal testing alternativesGenoskin, a biotechnology company headquartered in Toulouse, France and Salem, Massachusetts, launched NativeSkin access, an ex vivo human skin model available for daily online purchase at $99 in US markets. The product, sold in 8mm and 11mm diameters, allows researchers to test efficacy, absorption, and toxicity of topical compounds as an alternative to animal testing. The company, founded in 2011 as a spin-off from CNRS and Paul Sabatier University, positions this launch as a step toward making clinical testing faster and more accessible.BenzingaGenoskin Offers Live Skin Models To Bridge Animal, Human Testing: 'The Market Opportunity Is Huge' - AstrGenoskin, a French-American biotech company founded in 2011, provides ex-vivo human skin models derived from plastic surgery leftovers for pharmaceutical and biotech drug testing. The company, led by founder and CEO Pascal Descargues, reported $2.5 million in current revenue run-rate with 100% year-over-year revenue growth, operates facilities in France and the U.S. sourcing 40 skin samples weekly from 40 different donors, and has published data with major pharmaceutical companies including GlaxoSmithKline, AstraZeneca, Sanofi, Leo Pharma, and Unilever. The company is targeting a $1 billion market opportunity for skin toxicity testing, positioning its technology as a bridge between animal testing and clinical trials to address the 90% drug failure rate in clinical trials that occurs despite preclinical animal testing.Business InsiderA biotech company is collecting human skin donated from cosmetic surgery and keeping it alive for testingGenoskin collects leftover skin from cosmetic surgeries and keeps it alive in a gel for up to seven days, providing it to pharmaceutical and biotech companies for testing. The company says its method is an ethical alternative to animal testing and has developed product models for GlaxoSmithKline, Sanofi, and Unilever.